Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients

N. F. Olivieri, D. Matsui, P. P. Liu, L. Blendis, R. Cameron, R. A. McClelland, D. M. Templeton, G. Koren

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Despite the successes of deferoxamine (DFO) in the treatment and prevention of iron overload, an effective orally available iron chelating drug is needed, since erratic compliance with irritating, cumbersome parenteral infusions still results in fatal iron accumulation in many patients. Disorders of increased iron absorption should also benefit from the development of safe and effective iron chelating agents. Individuals with non-transfusion-dependent thalassemia (thalassemia 'intermedia'), exhibit excessive dietary iron absorption that can lead to serious iron loading by the second or third decade of life. An orally effective iron-chelating drug would have major therapeutic advantages for all these patients.

Original languageEnglish
Pages (from-to)9-11
Number of pages3
JournalBone Marrow Transplantation
Volume12
Issue numberSUPPL. 1
StatePublished - 1993
Externally publishedYes

Fingerprint

Dive into the research topics of 'Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients'. Together they form a unique fingerprint.

Cite this